PharmaResearch Co., Ltd. (KOSDAQ:214450)

Market Cap	3.17T -15.7%
Revenue (ttm)	536.29B +53.2%
Net Income	165.12B +79.4%
EPS	14,932.75 +67.0%
Shares Out	10.39M
PE Ratio	20.42
Forward PE	17.57
Dividend	3,700.00 (1.18%)
Ex-Dividend Date	Dec 29, 2025

Volume	105,137
Average Volume	129,325
Open	306,500
Previous Close	305,000
Day's Range	286,000 - 306,500
52-Week Range	278,500 - 713,000
Beta	n/a
RSI	42.18
Earnings Date	May 8, 2026

About PharmaResearch

PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214450

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.